Satellite Symposia

Company-sponsored Satellite Symposia take place at lunchtime as well as in the morning and in the evening. They provide cutting-edge information on interventional equipment and techniques.

 

Sunday, April 23
   
  13:00-13:45, Main Auditorium (Sala A1)
  BTG
SY 301
 
Integrating 90Y SIRT into clinical practice; the targeted and personalised
approach
   
  Moderator: E. Garin (Rennes/FR)
   
301.1
 
 
301.2
 
301.3
 
The current place of SIRT for the treatment of liver cancer patients; where are we now and where are we going
E. Garin (Rennes/FR)
Why do we need to personalise SIRT dosimetry; experiences from The Christie
J. Bell (Manchester/UK), T. Westwood (Manchester/UK)
Real life cost-effectiveness of radioembolisation in Italy for HCC treatment
S. Bhoori (Milan/IT), V. Mazzaferro (Milan/IT)
 

Sponsor Event Page

   
  13:45-14:30, Main Auditorium (Sala A1)
  Siemens Healthineers
SY 302
 
Complete tumour treatment while minimising collateral damage
Novel technologies in image-guided therapy
   
  Moderator: T.J. Vogl (Frankfurt/DE)
   
302.1
 
 
302.2
 
Advances in 3D imaging to improve guidance and outcomes during TACE
procedures
T.J. Vogl (Frankfurt/DE)
CT- and MR-guided tumour ablation
S. Clasen (Tübingen/DE)
   
   
  18:30-19:15, Auditorium 2 (Barria Room 1)
  Boston Scientific
SY 601 Controversies in DEB-TACE: optimising embolisation and drug delivery
   
  Moderators: J.I. Bilbao (Pamplona/ES), T.K. Helmberger (Munich/DE)
   
601.1
 
601.2
 
601.3
 
Is anoxia our goal?
F. Orsi (Milan/IT)
The use of 40 µm DEB-TACE in the treatment of HCC
G. Greco (Milan/IT)
Is drug delivery the main aim?
B. Guiu (Montpellier/FR)
   
   
Monday, April 24
   
  07:45-08:15, Auditorium 2 (Barria Room 1)
  Merit Medical
SY 701
 
HepaSphere™ drug-eluting Microspheres
Treating colorectal and neuroendocrine mets to the liver
   
  Moderator: S. Pluntke (Essen/DE)
   
701.1
 
 
701.2
 
 
Pharmacokinetic and safety of irinotecan loaded HepaSphere™ in CRC mets
to the liver
A. Gircys (Essen/DE)
HepaSphere™ drug-eluting Microspheres in the treatment of neuroendocrine
mets to the liver
G. Maleux (Leuven/BE)
   
   
  13:00-13:45, Main Auditorium (Sala A1)
  Medtronic
SY 1001 Advanced techniques in thermal ablation
   
  Moderator: D.J. Breen (Southampton/UK)
   
1001.1
 
1001.2
 
1001.3
 
400+ Emprint cases experience: what we learned
F. Orsi (Milan/IT)
Complex and unusual cases management
B. Gonçalves (Porto/PT)
New technology in the treatment of bone metastasis
J. Garnon (Strasbourg/FR)
   
   
  13:45-14:30, Main Auditorium (Sala A1)
  Terumo Europe
SY 1002 GREAT DEBATE in liver intra-arterial therapies
   
  Oil vs. polymer for the treatment of HCC?
   
  Moderator: V. Vilgrain (Clichy/FR)
   
1002.1
 
1002.2

 
cTACE/B-TACE
T. de Baère (Villejuif/FR)
DEM-TACE
F. Veloso Gomes (Lisbon/PT)
Moderated discussion
   
  To poison or to irradiate mCRC?
   
  Moderator: H. Prenen (Leuven/BE)
   
1002.3
 
1002.4

 
DEM-TACE
P.L. Pereira (Heilbronn/DE)
TARE
A. Denys (Lausanne/CH)
Moderated discussion
   
   
Tuesday, April 25
   
  13:00-13:45, Main Auditorium (Sala A1)
  Guerbet
SY 1701 Conventional TACE and beyond
   
  Moderator: T.J. Vogl (Frankfurt/DE)
   
1701.1
 
1701.2
 
1701.3
 
1701.4
 
1701.5
 
Introduction
T.J. Vogl (Frankfurt/DE)
cTACE to risk-stratify HCC patients
T.J. Vogl (Frankfurt/DE)
Proof on Lipiodol® unique properties!
T. de Baère (Villejuif/FR)
cTACE & combined therapies: the oncologist perspective
T. de Baère (Villejuif/FR)
Questions
T.J. Vogl (Frankfurt/DE)
   
   
  13:45-14:30, Main Auditorium (Sala A1)
  Sirtex Medical Europe GmbH
SY 1702
 
SIR-Spheres® Y-90 resin microspheres – pushing the evidence
forward for interventional oncology
   
  Moderator: J.I. Bilbao (Pamplona/ES)
   
1702.1
 
1702.2
 
1702.3
Current and future data for Y-90 resin microspheres in mCRC
P. Gibbs (Melbourne, VIC/AU)
Breaking news in HCC: Latest evidence for Y-90 resin microspheres
V. Vilgrain (Clichy/FR)
Panel discussion: Implications of the new HCC data in clinical practice
   
   
Wednesday, April 26
   
  10:00-10:45, Main Auditorium (Sala A1)
  Toshiba Medical Systems Europe
SY 2103 Infinix-i 4D CT: push your limits in interventional oncology
   
  Moderator: A. Denys (Lausanne/CH)
   
2103.1
 
Liver interventional oncology: first European experience with Infinix-i 4D CT
B. Guiu (Montpellier/FR)
   
   

TOP